Sedana Medical AB (SEDANA) Fair Value & Analysis
Healthcare · SE · Market cap 875M SEK
Fair value as of: Aug 13, 2026
From 3 valuation models · updated today
Fair value updated Aug 13, 2026, revised from kr 0.7100 to kr 6.80 (+857.7%) since Jul 14, 2026. Share price +29.1% over the past month.
Below-average quality, and screening another 40% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 9.67). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (kr 3.64 to kr 9.67). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 6.88 – kr 107.10 · fair‑value band kr 3.64 – kr 9.67 · the kr 11.28 price screens above the kr 6.80 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sedana Medical AB (SEDANA) currently trades at kr 11.28, while our model-based Fair Value estimate is kr 6.80, implying the stock looks roughly 39.7% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Sedana Medical AB generated revenue of 196M SEK at a net margin of -20.2%. Revenue declined 7.1% year over year. It earns a return on equity of -4.3%. The balance sheet holds a net cash position of 86.3M SEK. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 3.64 (bear case) to kr 9.67 (bull case); at kr 11.28, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -40%, SEDANA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (kr 6.08) versus Dividend Discount (kr 0.5900). Highest evidence: Gordon GGM (70).
Notify me when SEDANA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Spain, Germany, and internationally.
Full company description
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Spain, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a syringe with a connection to fit the connector on the agent line of the Sedaconda ACD and Sedana Medical filling adapters; Sedaconda ACD starter kit; Sedaconda (Isoflurane) for maintenance of sedation in intubated or tracheostomised mechanically ventilated adult and paediatric patients from 3 years of age; Sedaconda Filling Adapter, a single-use medical device; FlurAbsorb Pro-L and Pro-S; FlurAbsorb and Mounts; Scavenging Tube, a one piece pre-connected tube, that is designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; and Mindray exhaust connector enables to connect the exhaust of the ventilator to an active or passive scavenging system. The company was founded in 1999 and is headquartered in Danderyd, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sedana Medical AB reported revenue of kr 200M in FY2025 versus kr 159M in FY2021, a compound +5.9%/yr. Reported net income was −kr 59.2M in FY2025.
SEDANA screens 40% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 349 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Sedana Medical AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sedana Medical AB (SEDANA) overvalued or undervalued?
What is the fair value of SEDANA?
What is the quality score of SEDANA?
What is the revenue of Sedana Medical AB (SEDANA)?
What is the net profit margin of SEDANA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sedana Medical AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.